 We have been studying a kind of chemia called MF-fusion chemia. We already knew it was driven by MF-fusion protein. And the MF-fusion protein might be able to fuse together with around 120 different fusion patterns. So that's why it's very difficult to stop it. So based on our study, we found that a protein is called ZFB64. We are able to find ZFB64 that can regulate the promoter of all the MF-fusion chemia. So when we shut off ZFB64, we are able to shut off all the MF-fusion proteins. Having found that MF-fusion chemia is specifically addicted to the ZFB64 protein, what we want to do next is find a way to target ZFB64. So it can be used in clinical trial.